
Monitoring the Tariff Impact on Benefits...
Health care costs in the U.S. are overwhelmingly driven by prescription drug prices, which continue to outpace inflation and international benchmarks, straining patients, providers and public coffers. Direct Cost Increases for Drugmakers Johnson & Johnson alone expects to absorb roughly $400 million in tariff‐related expenses this year, driven